Kathleen Borthwick, the Chief Financial Officer of Passage BIO, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines ...

Passage Bio, Inc., a biotechnology firm specializing in biological products, has transferred its stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transition, ...

Passage Bio, Inc., disclosed in an 8-K filing on January 8, 2025, that it has initiated a restructuring plan aimed at ceasing lab operations at its leased laboratory space in Hopewell, New Jersey ...

Outlines Strategic Priorities Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial ...

(RTTNews) - Passage Bio (PASG), a clinical-stage genetic medicines ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Passage Bio (NASDAQ:PASG) just reported results for the fourth quarter of 2023. Passage Bio reported earnings per share of -30 cents. This was above the analyst estimate for EPS of -40 cents.

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced a series of agreements to out-license its three ...

Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA. Read More on PASG: Passage Bio NewsMORE Related Stocks Indices Commodities ...

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared updated findings from its ongoing Phase 1/2 upliFT-D clinical trial, which evaluates PBFT02 as a potential treatment for ...

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that Will Chou, M.D., the president and chief executive officer of the company, will be presenting at the prestigious Guggenheim ...

Nasdaq (Nasdaq: NDAQ) announced today that in 2024, it welcomed 171 initial public offerings (IPOs), raising a total of $22.7 billion. A total of 123 operating companies and 48 SPACs listed on ...